ong-term StaphyloCoccus aureus decolonizAtion in patients on home parentRal nutRition: a randomized multicEnter tRial.
- Conditions
- contamination with own skin bacteria10004018S. aureus carriage10017977
- Registration Number
- NL-OMON44280
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Trial is onging in other countries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 63
- Patient is fully able to understand the nature of the proposed intervention.
- Patient is diagnosed with intestinal failure and on HPN and/or fluid replacement
- Written informed consent by the patient before entering the trial.
- Age * 18 years.
- Estimated life expectancy * 1 year.
- Patient colonized with S. aureus.
- Cannot be expected to comply with the trial plan (substance abuse, mental condition).
- Pregnant or breastfeeding women.
- Continuous exposure to MRSA (e.g. pig farmer).
- Allergy for chlorhexidine and betadine.
- No options for oral and/or topical antibiotics due to allergies and/or resistance.
- Active S. aureus infection.
- Currently on treatment with antibiotics active against S. aureus.
- Decolonization (including mupriocin) treatment in the previous two months.
- The presence of an unremovable nasal foreign body.
- AST and ALT levels more than five times the upper limit of normal or liver failure.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary outcome: proportion of patients eradicated for S. aureus (nose, throat,<br /><br>rectum, exit-site catheter) during one year.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary outcomes: long-term antimicrobial resistance, adverse events, patient<br /><br>compliance, incidence of (S. aureus)<br /><br>infections, catheter removals, mortality rates, S. aureus transmission routes,<br /><br>quality of life and costs.</p><br>